PLENO HYPERSENSITIVITAS

8/18/2019 PLENO HYPERSENSITIVITAS

1/30

GROUP 3

Andika Razzanur 1218011014 Asep Setya Rini 1218011023 Eduard 1218011042 Gheavani Legowo12180110!

"uzai#ah 12180110$2 %arina &e''ova 121801108! &i(o A'drin Avesina 121801111 Sartika Sa)tri 121801113* Se+a Riandini121801113$ Si'vi ,iroatu' Aini 1218011143 Ste-hani Gista L 121801110 .sa zsa /eryana 12180111** Anasthasia / A 12180111*8


2/30


3/30

LEAR&&G 5E67ES


4/30

"9:ERSE&S779

"ypersensitivity re-ers to e;(essive<undesira'e rea(tions produ(ed y

the nor#a' i##une syste#= "ypersensitivity rea(tions re>uire a

pre?sensitized @i##une state o- the

host=


5/30

"9:ERSE&S779

TYPE 1 TYPE 2 TYPE 3 TYPE 4

gE ediated

6'assi( A''ergy

gGBgediated

r( 'ysis

gG ediated

##une(o#p'e;Cisease

7 (e''

Ce'ayed 7ype

"ypersensitivity


6/30


7/30

S9S7E6 LD:DSER97"EA7SDS @SLE

6hroni( #u'tisyste# ina##atorydisease

Asso(iated with anor#a'ities o-i##une syste# Resu'ts -ro# intera(tions a#ong

geneti(< hor#ona'< environ#enta'< andi##uno'ogi( -a(tors


8/30

&6CE&6E

SLE aFe(ts 2 to 8 persons per 100


9/30

:A7":"9SLG9

Autoi##une rea(tions dire(tedagainst (onstituents o- (e''nu('eus< C&A

Antiody response re'ated to and

7 (e'' hypera(tivity


10/30


11/30

6L&6AL A&/ES7A7&


12/30

CERA7LG6A&/ES7A7&

SA& &E6%

CE/R79


13/30

us(u'oske'eta'

:o'yarthra'gia with #orning stiFness

ArthritisSwan ne(k )ngers

D'nar deviation

Su'u;ation with hyper'a;ity o- Hoints


14/30

6ardiopu'#onary 7a(hypnea

:'eurisy

Cysrhyth#ias

A((e'erated 6AC

:eri(arditis

Rena' Lupus nephritis

Ranging -ro# #i'd proteinuria tog'o#eru'onephritis

:ri#ary goa' in treat#ent is s'owing theprogression


15/30

&ervous syste#

Genera'izedB-o(a' seizures

:eriphera' neuropathy

6ognitive dys-un(tionCisorientatione#ory de)(its:sy(hiatri( sy#pto#s


16/30

"EA7LG6

/or#ation o- antiodies against 'ood (e''sAne#ia

Leukopenia 7hro#o(ytopenia

6oagu'opathy

Anti?phospho'ipid antiody syndro#e


17/30

CAG&S76 S7DCES


18/30

CAG&S76 7ES7

66 -or he#ato'ogi( pro'e#s

DA -or 'upus nephritis

I?rays o- aFe(ted Hoints

6hest ;?ray -or pu'#onarypro'e#s

E6G -or (ardia( pro'e#s


19/30

A&AGEE&7 A&C 7REA7E&7

Crug therapy&SACs

Anti#a'aria' drugsSteroid?sparing drugs

6orti(osteroids

##unosuppressive


20/30

A(ute interventiononitor weight and J

6o''e(t 24?hour urine sa#p'eAssess neuro'ogi(a' status

E;p'ain nature o- disease

:rovide support

A#u'atory and ho#e (are

Reiterate that adheren(e to treat#ent doesnot ne(essari'y ha't progression

ini#ize e;posure to pre(ipitating -a(tors K-atigue< sun< stress< in-e(tion< drugs


21/30

SYNDROME

severe e;pression o- erythe#a#u'ti-or#e

invo'ves the skin and the #u(ous#e#ranesora'< nasa'< eye< vagina'< urethra'< G< and

'ower respiratory tra(t #u(ous #e#ranes potentia' -or severe #oridity and even

death=


22/30

E79LG

n-e(tion

Crug?indu(ed

a'ignan(y?re'ated

6o''agen vas(u'ar disease diopathi(

2?0 o- (ases


23/30

Haynes, B.F. and Fau!, ".S. #2$$1% D!s&'de's &( )*e!++une sys)e+. n P'!!-es &( n)e'na Med!!ne


24/30

:athophysio'ogy

&ot (o#p'ete'y understood

Epide#io'ogy 0=4?1=2 (ases per #i''ion per year

a'e?to?-e#a'e ratio is 2M1

6au(asian predo#inan(e has een reported

orta'ity rate M 3?1 @or 30


25/30

A&/ES7A7&

S0!n Erythe#atous #a(u'es e;tending over

the -a(e ne(k< trunk and e;tre#ities

Eyes :eriorita' redness and swe''ing=

M&u)*Mswe''ing o- the 'ipsJ #i'd u'(eration=


26/30

*es)M

('ear good air entry i'atera''y


27/30


28/30

CAG&S76

Skin iopsy

"istopato'ogy

'ood tests


29/30

7REA7E&7

supportive re#ova' o- the oFending agent rep'a(e#ent o- uid 'osses

si#i'ar to urn vi(ti#s ana'gesi(s a'' drugs started within the past #onth

shou'd e dis(ontinued avoid Si'vadene @si'ver su'-adiazine


30/30

7REA7E&7

7he ro'e o- (orti(osteroids in S5S and 7E& is high'y(ontroversia' ased on a review o- the 'iterature< there does not appear to e

a (onsensus on the use o- steroids in the treat#ent o- S5S and 7E&

Asepti( te(hni>ue to avoid in-e(tion Dse o- adhesive #ateria'< oint#ents< and (rea#s shou'd eavoided :atients shou'd e (overed in a ('ean white sheet

Ceride#ent o- ne(roti( tissue #ay e ne(essary

:rophy'a(ti( antiioti( therapy is no 'onger given 6rossrea(tivity with the drug that initiated the 7E& the risk o- se'e(ting -or resistant organis#s

PLENO HYPERSENSITIVITAS

Documents

Transcript of PLENO HYPERSENSITIVITAS